Compare Charter Communications Inc (CHTR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charter Communications Inc vs GeneDx Holdings Corp — how do they compare? Charter Communications Inc trades at $156.89 (market cap $18.81B), while GeneDx Holdings Corp trades at $81.66 (market cap $2.44B). The key difference: Charter Communications Inc is far larger — about 7.7× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Charter Communications Inc nearer its low. Which is the better fit depends on your goals.
| CHTR | WGS | |
|---|---|---|
Market Cap | $18.81B | $2.44B |
Sector | Media | Technology |
52-Week High | $282.74 | $167.51 |
52-Week Low | $123.31 | $34.51 |
Enterprise Value | $115.01B | $2.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charter Communications Inc
Charter is the product of the 2016 merger of three cable companies, each with a decades-long history in the business: Legacy Charter, Time Warner Cable, and Bright House Networks. The firm now holds networks capable of providing television, internet access, and phone services to roughly 54 million U.S. homes and businesses, around 40% of the country. Across this footprint, Charter serves 29 million residential and 2 million commercial customer accounts under the Spectrum brand, making it the second-largest U.S. cable company behind Comcast. The firm also owns, in whole or in part, sports and news networks, including Spectrum SportsNet (long-term local rights to Los Angeles Lakers games), SportsNet LA (Los Angeles Dodgers), SportsNet New York (New York Mets), and Spectrum News NY1.
Read more on CHTR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
